166 related articles for article (PubMed ID: 12914401)
1. [Drug treatment of immune hyperthyroidism (Basedow disease). Patient selection, long-term follow-up and prevention of recurrence].
Quadbeck B; Hörmann R; Janssen OE; Mann K
Internist (Berl); 2003 Apr; 44(4):440-8. PubMed ID: 12914401
[TBL] [Abstract][Full Text] [Related]
2. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
[TBL] [Abstract][Full Text] [Related]
3. [Basedow disease hyperthyroidism--is there a therapeutic standard? Conservative therapy].
Schumm-Draeger PM
Zentralbl Chir; 1997; 122(4):224-6. PubMed ID: 9221630
[TBL] [Abstract][Full Text] [Related]
4. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
5. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
6. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
7. Antithyroid drug regimen for treating Graves' hyperthyroidism.
Abraham P; Avenell A; Watson WA; Park CM; Bevan JS
Cochrane Database Syst Rev; 2005 Apr; (2):CD003420. PubMed ID: 15846664
[TBL] [Abstract][Full Text] [Related]
8. Antithyroid drug regimen for treating Graves' hyperthyroidism.
Abraham P; Avenell A; McGeoch SC; Clark LF; Bevan JS
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003420. PubMed ID: 20091544
[TBL] [Abstract][Full Text] [Related]
9. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
10. [Administration of levothyroxine in the treatment of Basedow disease].
Hörmann R
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():47-52. PubMed ID: 10355050
[TBL] [Abstract][Full Text] [Related]
11. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
Masiello E; Veronesi G; Gallo D; Premoli P; Bianconi E; Rosetti S; Cusini C; Sabatino J; Ippolito S; Piantanida E; Tanda ML; Chiovato L; Wiersinga WM; Bartalena L
J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
[TBL] [Abstract][Full Text] [Related]
12. [Basedow disease--thyrostatic drugs combined with thyroxine?].
von Werder K
Fortschr Med; 1996 May; 114(14):6-7. PubMed ID: 8707240
[No Abstract] [Full Text] [Related]
13. Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review.
Li J; Bai L; Wei F; Wei M; Xiao Y; Yan W; Wei J
Front Endocrinol (Lausanne); 2020; 11():560157. PubMed ID: 33569041
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
15. [Problems and new developments in the management of Graves' disease: medical therapy].
Quadbeck B; Janssen OE; Mann K
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():37-44. PubMed ID: 15255312
[TBL] [Abstract][Full Text] [Related]
16. [Hyperthyroidism in Graves' disease--antithyroid drug treatment].
Schumm-Draeger PM
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():41-5. PubMed ID: 10355049
[TBL] [Abstract][Full Text] [Related]
17. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
18. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
19. Response to methimazole in Graves' disease. The European Multicenter Study Group.
Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
[TBL] [Abstract][Full Text] [Related]
20. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
